⌕
Xeris Biopharma Holdings · XERS · Nasdaq
Tenet 48 · Mixed
Compare
$16.66+0.06%At closeTenet 48 · Mixed
$16.66+0.01 (+0.06%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Xeris Biopharma Holdings (XERS) Stock

Xeris Biopharma Holdings (XERS) closed at $16.66 on Nov 13, 2026; its Tenet Score is 48 of 100 against 297 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

22 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$16.66
Nov 13, 2026
Market cap
$3.0B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
5.25 – 16.88
low → high · as of close, Nov 13, 2026
Tenet Score
48/100
Mixed · 297 Healthcare peers

Industry: Drugs

Xeris Biopharma Holdings Inc scores 48/100. Mixed. Strongest on growth, value is the soft spot versus 297 Healthcare peers.

Tenet Score · vs sector

n=297
48/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
11
Quality
65
Health
26
Growth
91

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityCHealthFGrowthAMomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
62.4×
price to book value
P/S
8.3×
price to fiscal 2025 sales
ROE
−27%
return on equity
Operating margin
8.5%
fiscal 2025, before interest and tax
Net margin
−1.8%
of revenue kept
Current ratio
2.15
current assets to liabilities
Net debt / EBITDA
0.9×
leverage, net of cash
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Xeris Biopharma Holdings Inc

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the tre…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=297) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 66 US ETFs · top wrappers by weightSee all ETFs holding XERS →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Xeris Biopharma Holdings in?

Xeris Biopharma Holdings is in the Healthcare sector and the Drugs industry.

What is Xeris Biopharma Holdings' Tenet Score?

Xeris Biopharma Holdings' Tenet Score is 48 out of 100, ranked against 297 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.